A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)-Reference-Cited by-同舟云学术

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

Published:2016-09-07 Issue:22 Volume:122 Page:3519-3528
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Makker Vicky¹²,Recio Fernando O.³,Ma Ling⁴,Matulonis Ursula A.⁵,Lauchle Jennifer O.⁶,Parmar Hema⁶,Gilbert Houston N.⁶,Ware Joseph A.⁶,Zhu Rui⁶,Lu Shan⁶,Huw Ling-Yuh⁶,Wang Yulei⁶,Koeppen Hartmut⁶,Spoerke Jill M.⁶,Lackner Mark R.⁶,Aghajanian Carol A.¹²

Affiliation:

1. Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center; New York New York

2. Weill Cornell Medical College; New York New York

3. South Florida Center for Gynecologic Oncology; Boca Raton Florida

4. Rocky Mountain Cancer Centers; Lakewood Colorado

5. Dana-Farber Cancer Institute; Boston Massachusetts

6. Genentech Inc; South San Francisco California

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.